HC Wainwright & Co. Maintains Buy on ADMA Biologics, Raises Price Target to $5
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju maintains a Buy rating on ADMA Biologics and raises the price target from $4.5 to $5.
August 10, 2023 | 11:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ADMA Biologics' price target has been raised from $4.5 to $5 by HC Wainwright & Co. The firm maintains a Buy rating on the stock.
The raised price target indicates the analyst's increased confidence in the company's future performance. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100